[go: up one dir, main page]

WO2005108987A3 - Determination of osteoprotegerin for the prognosis of cardiovascular disorders - Google Patents

Determination of osteoprotegerin for the prognosis of cardiovascular disorders Download PDF

Info

Publication number
WO2005108987A3
WO2005108987A3 PCT/NO2005/000150 NO2005000150W WO2005108987A3 WO 2005108987 A3 WO2005108987 A3 WO 2005108987A3 NO 2005000150 W NO2005000150 W NO 2005000150W WO 2005108987 A3 WO2005108987 A3 WO 2005108987A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
osteoprotegerin
determination
cardiovascular disorders
cardiovascular disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NO2005/000150
Other languages
French (fr)
Other versions
WO2005108987A2 (en
Inventor
Rune Jemtland
John Kjekshus
Thor Ueland
Arne Yndestad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKSHOSPITALET - RADIUMHOSPITALET HF
RIKSHOSPITALET RADIUMHOSPITALE
Original Assignee
RIKSHOSPITALET - RADIUMHOSPITALET HF
RIKSHOSPITALET RADIUMHOSPITALE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKSHOSPITALET - RADIUMHOSPITALET HF, RIKSHOSPITALET RADIUMHOSPITALE filed Critical RIKSHOSPITALET - RADIUMHOSPITALET HF
Publication of WO2005108987A2 publication Critical patent/WO2005108987A2/en
Publication of WO2005108987A3 publication Critical patent/WO2005108987A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Thus, the present invention provides a method, an assay and a kit for providing a prognosis of patients suffering from a cardiovascular disorder. It was surprisingly found that the significant increase in Osteoprotegrin concentration in patients (as well as animals) are useful as a prognostic tool to predict the clinical outcome, complications and mortality following a cardiovascular disorder, such as but not limited to acute myocardial infarction.
PCT/NO2005/000150 2004-05-07 2005-05-06 Determination of osteoprotegerin for the prognosis of cardiovascular disorders Ceased WO2005108987A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20041874 2004-05-07
NO20041874 2004-05-07

Publications (2)

Publication Number Publication Date
WO2005108987A2 WO2005108987A2 (en) 2005-11-17
WO2005108987A3 true WO2005108987A3 (en) 2006-05-26

Family

ID=35320842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2005/000150 Ceased WO2005108987A2 (en) 2004-05-07 2005-05-06 Determination of osteoprotegerin for the prognosis of cardiovascular disorders

Country Status (1)

Country Link
WO (1) WO2005108987A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ201180A3 (en) * 2011-02-14 2012-08-22 Ústav informatiky AV CR, v. v. i. Method of identifying persons with increased genetic risk of myocardial infarction occurrence
CZ303405B6 (en) * 2011-02-14 2012-08-29 Ústav informatiky AV CR, v. v. i. Method of identifying persons with increased genetic risk of myocardial infarction occurrence
CZ303458B6 (en) * 2011-02-14 2012-09-19 Ústav informatiky AV CR, v. v. i. Method for identifying persons with increased genetic risk of decease after myocardial infarction
WO2013190041A1 (en) * 2012-06-22 2013-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the survival time of post acute myocardial infarction patients

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALTUN A ET AL: "Decreased serum osteoprotegerin levels in patients with cardiac syndrome X", JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 27, no. 9, October 2004 (2004-10-01), pages 839 - 843, XP009059886, ISSN: 0391-4097 *
ANONYMOUS: "Manual: Osteoprotegerin, Elisa for the in vitro determination of OPG in serum, plasma, urine and cell culture supernatant", INTERNET, 22 March 2004 (2004-03-22), pages COVERPAGE,2,15 - 24 *
ANONYMOUS: "Osteoprotegerin [OPG]", INTERNET, XP002362788, Retrieved from the Internet <URL:http://www.immundiagnostik.com/> [retrieved on 20060113] *
JONO SHUICHI ET AL: "Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.", CIRCULATION. 3 SEP 2002, vol. 106, no. 10, 3 September 2002 (2002-09-03), pages 1192 - 1194, XP002362640, ISSN: 1524-4539 *
KEES MATHIAS ET AL: "Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera", THROMBOSIS AND HAEMOSTASIS, vol. 93, no. 1, January 2005 (2005-01-01), pages 70 - 75, XP009059907, ISSN: 0340-6245 *
KIECHL STEFAN ET AL: "Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.", CIRCULATION. 11 MAY 2004, vol. 109, no. 18, 11 May 2004 (2004-05-11), pages 2175 - 2180, XP002362641, ISSN: 1524-4539 *
UELAND T ET AL: "Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,, vol. 44, no. 10, 16 November 2004 (2004-11-16), pages 1970 - 1976, XP004681171, ISSN: 0735-1097 *
UELAND THOR ET AL: "Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess: Possible role in bone homeostasis", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 145, no. 6, December 2001 (2001-12-01), pages 685 - 690, XP002362639, ISSN: 0804-4643 *

Also Published As

Publication number Publication date
WO2005108987A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2006023880A3 (en) Compounds and methods for the characterization of oligonucleotides
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2007002677A3 (en) Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP2154245A3 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
WO2008082713A3 (en) Integrated semiconductor bioarray
WO2007103770A8 (en) Compositions and methods for analyzing renal cancer
EP2392678A3 (en) Prognosis prediction for colorectal cancer
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2004044218A3 (en) Methods and materials for examining pathways associated with glioblastoma progression
WO2006052823A3 (en) Biomarkers for prostate cancer metastasis
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
EP1363125A3 (en) Transcription factor profiling on a solid surface
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
WO2005118836A3 (en) Hif prolyl hydroxylase activity assay
WO2004111654A3 (en) Serum biomarkers in ischaemic heart disease
WO2004041215A3 (en) Methods for treating gastroesophageal reflux disease
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2006063133A3 (en) Biomarker for inflammatory bowel disease
WO2005108987A3 (en) Determination of osteoprotegerin for the prognosis of cardiovascular disorders
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase